Healthy adult
Conditions
Interventions
Intake of food containing Pomegranate Punicalagin, 5-fold quantity of recommended daily intake, for 4 weeks
Intake of food not containing Pomegranate Punicalagin, for 4 weeks
Sponsors
EP Mediate Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Male and female aged 20 to 64 (2) Subjects who fully understand the purpose and content of this study and voluntarily agree to participate in the study
Exclusion criteria
Exclusion criteria: (1) Subjects who have already been intaking food, pharmaceuticals, or quasi-drugs enhanced with Pomegranate Punicalagin at least once a week during the pre-examination (2) Subjects who intake pomegranates or pomegranate juice three or more days a week (3) Subjects who have had abnormalities in clinical test values or liver function or cardiopulmonary function and are judged to be unsuitable for participation in the study (4) Subjects who are at risk of developing allergies related to the study (5) Subjects with a disease requiring regular medication (Both external and internal medications), with a disease currently being treated (excluding dry eyes and tooth decay) or with a history of a serious disease that required medication (6) Subjects whose pre-intake test results are significantly outside the reference range (7) Subjects who work in shifts, late-night shifts, or have other irregular lifestyles (8) Subjects who have participated or plan to participate in other studies within one month of the start of the study (9) Subjects who intend to become pregnant or lactating (10) Subjects who are judged to be unsuitable for participation in the study based on their responses to the lifestyle questionnaire (11) Subjects who are judged as unsuitable for the study by the investigator for other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hematologic test, Blood biochemistry test, Urine test, Blood pressure/pulsation, Weight/body mass index, Medical Interview, before and 2, 4 weeks after intake and 2 weeks after the end of intake period and Adverse events thorough the study | — |
Countries
Japan
Contacts
Public ContactSaki Fukuchi
EP Mediate Co., Ltd. Development Department Trial Planning Section
Outcome results
None listed